YD Bio Ltd (YDES) - Form 20-F Summary
Business Context and Reporting Period
Company: YD Bio Ltd (Cayman Islands exempted company, listed on Nasdaq Global Market as "YDES").
Reporting Period: Fiscal year ended December 31, 2025.
Business Overview: A biotechnology company focused on regulated diagnostics (DNA methylation-based oncology testing), life science clinical services, and healthcare product commercialization. Operations include Laboratory Developed Tests (LDTs) for cancer detection in the U.S. and distribution of medical products in Taiwan.
Recent Corporate Action: Completed a reverse recapitalization business combination with Breeze Holdings Acquisition Corp. on August 28, 2025.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (USD) | 2024 (USD) |
|---|---|---|
| Net Revenue | $596,817 | $510,360 |
| Gross Profit | $167,410 | $155,356 |
| Gross Margin | 28.1% | 30.4% |
| Net Loss | $(8,311,316) | $(1,411,559) |
| Operating Loss | $(5,271,721) | $(1,461,930) |
| Cash and Cash Equivalents | $6,007,615 | $3,132,298 |
| Warrant Liabilities | $14,991,482 | $0 |
| Accumulated Deficit | $(10,238,359) | $(1,927,043) |
Liquidity: Cash balance increased to $6.0 million primarily due to a $13.2 million PIPE financing and business combination proceeds, offset by operating losses and capital expenditures.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 17% to $597k, driven by higher pharmaceutical sales (Keytruda) and new product launches, partially offset by a shift to lower-margin products.
- Expense Surge: Total operating expenses increased 236% to $5.4 million. Increases were driven by professional fees for restructuring ($1.1M), R&D expenses for licensed patents ($1.1M), and staff costs ($1.3M).
- Warrant Liability Impact: A non-cash loss of $3.2 million was recorded due to the change in fair value of warrant liabilities assumed in the business combination.
- Going Concern: The company has incurred recurring losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern without additional financing.
Guidance, Outlook, and Risks
Outlook & Strategy:
- Acquisitions: Entered a non-binding MOU to merge with EG BioMed (Jan 2026) and a binding LOI to acquire Safe Save Medical Cell Sciences (SSMC) for ~$26.9M (Jan 2026).
- Product Pipeline: Advancing pancreatic and breast cancer blood tests (LDT framework) and exosome-based eye treatments (Phase I trials expected 2027).
- Capital Needs: Expects to require $2.4M–$2.7M for 2026 operations and $9M–$10M for capital expenditures (real estate and facilities).
Key Risks:
- Regulatory: No FDA approval for cancer tests yet; reliance on LDT framework which faces regulatory uncertainty. FDA restructuring may delay approvals.
- Financial: Substantial doubt regarding going concern; reliance on future equity/debt financing which may cause dilution.
- Concentration: Top three customers (Novartis, Zuelling, Alcon) accounted for 53.7% of 2025 revenue. Top supplier (3D Global) accounted for 83.7% of purchases.
- Geopolitical: Operations heavily concentrated in Taiwan; risks related to China-Taiwan relations and currency fluctuations.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure additional financing to cover the projected $11.4M–$12.7M cash burn (operations + CapEx) for 2026.
- Related Party Transactions: Review the terms of the 3D Global and EG BioMed license agreements, noting the CEO's significant ownership in both entities and the milestone payment obligations.
- Warrant Liability Volatility: Monitor the fair value of the $15M warrant liability, as fluctuations will directly impact reported net income.
- Regulatory Pathway: Confirm the status of the FDA de novo application for breast cancer monitoring and the LDT compliance status for pancreatic testing.
- Acquisition Certainty: Assess the likelihood of closing the SSMC acquisition ($26.9M) and EG BioMed merger, given the company's current liquidity constraints.